NCT06319235View on ClinicalTrials.gov

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Surgical Site InfectionStaphylococcus Aureus InfectionPseudomonas Aeruginosa InfectionBacterial InfectionsSurgical Wound Infection
Interventions
DRUG

IMP

DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.

DRUG

Placebo

0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C

Trial Locations (1)

602 00

RECRUITING

St. Anne's University Hospital Brno, Brno

All Listed Sponsors
lead

MB PHARMA s.r.o.

INDUSTRY